Healthcare

Portfolio spotlight

Our Portfolio
benchling
benchling

Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.

Milestones
  • 2012 Founded
  • 2019 Partnered, Series C
benchling_graphic
delfi
delfi

Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.

Milestones
  • 2019 Founded
  • 2019 Partnered, Seed
Partner
delfi_graphic
encoded_therapeutics-rectangle
encoded_therapeutics-rectangle

Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.

Milestones
  • 2014 Founded
  • 2019 Partnered, Series C
Partner
encoded_therapeutics_graphic
gilead NASDAQ: GILD
gilead

Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.

Milestones
  • 1987 Founded
  • 1987 Incubated by Menlo Ventures
  • 1992 IPO; NASDAQ: GILD
gilead_graphic

H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
pillpackAcquired by Amazon
pillpack

PillPack is a full-service pharmacy that delivers a better, simpler experience through convenient packaging, modern technology, and personalized service.

Milestones
  • 2013 Founded
  • 2015 Partnered, Series C
  • 2018 Acquired by Amazon
pillpack_graphic
NASDAQ: PLRX

Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Milestones
  • 2015 Founded
  • 2018 Partnered, Series B
  • 2020 IPO; NASDAQ: PLRX
Partner
pliant_therapeutics_graphic
recursion NASDAQ: RXRX
recursion

Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.

Milestones
  • 2013 Founded
  • 2017 Partnered, Series B
  • 2021 IPO; NASDAQ: RXRX
recursion_graphic

Our perspective

Clear all
List view Grid view
Filters

Video: Early Cancer Detection With Delfi

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

Video: Reengineering Drug Discovery With Recursion
Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna

Partnership
is our
purpose.

mental health care graphic
Carefully Crafted Digital Approaches Can Improve Youths’ Mental Health Care
Announcing the Digital Health Founder’s Fellowship
Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences

Don’t Forget the Pipes! Why Insurtech Infrastructure Is Poised to Be Huge!

Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.

Ophelia Health: Fighting the Opioid Epidemic by Making the Best Care Accessible

Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.

It’s Time to Crack the Complex Code of Benefits Tech
Life Science Is Being Transformed by Vertical SaaS
The 5 Ps of Therapeutics Investing at Menlo
Our Investment in Riva Health: Building the Future of Cardiovascular Healthcare

Roadblocks and Opportunities in Electronic Healthcare Records: A Conversation with Particle Founder Troy Bannister

As part of the 21st Century Cures Act, the White House established rules compelling payers and hospitals to make patient health data easily shareable by modern technology standards.

Join a
Menlo-backed
company.

Doubling Down on H1: Menlo Co-Leads Series B, Eight Months After Leading Series A
Video: Early Cancer Detection With Delfi

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

March 9, 2023Greg Yap
Video: Reengineering Drug Discovery With Recursion

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

March 9, 2023Greg Yap and Johnny Hu
Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna

Cancer remains one of the leading causes of death in the U.S. and worldwide.

January 11, 2023Johnny Hu
Carefully Crafted Digital Approaches Can Improve Youths’ Mental Health Care

In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.

December 7, 2022Greg Yap and Derek Xiao
Announcing the Digital Health Founder’s Fellowship

Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship

December 6, 2022Greg Yap
Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences

Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.

May 25, 2021JP Sanday
Don’t Forget the Pipes! Why Insurtech Infrastructure Is Poised to Be Huge!

Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.

April 27, 2021Steve Sloane
Ophelia Health: Fighting the Opioid Epidemic by Making the Best Care Accessible

Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.

April 22, 2021Greg Yap and Croom Beatty
It’s Time to Crack the Complex Code of Benefits Tech

The COVID-19 pandemic changed the world of benefits forever. Companies rethought the traditional office paradigm and re-evaluated the suite of benefits that provide a strong work experience for employees.

April 21, 2021Steve Sloane
Life Science Is Being Transformed by Vertical SaaS

We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.

April 14, 2021Matt Murphy, JP Sanday and Greg Yap
The 5 Ps of Therapeutics Investing at Menlo

At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.

March 31, 2021Greg Yap
Our Investment in Riva Health: Building the Future of Cardiovascular Healthcare

Nearly half of U.S. adults—108 million people—have high blood pressure, which is the #1 controllable risk for both heart disease and stroke, the two leading worldwide causes of death.

March 17, 2021Greg Yap
Roadblocks and Opportunities in Electronic Healthcare Records: A Conversation with Particle Founder Troy Bannister

As part of the 21st Century Cures Act, the White House established rules compelling payers and hospitals to make patient health data easily shareable by modern technology standards.

January 11, 2021Croom Beatty
Doubling Down on H1: Menlo Co-Leads Series B, Eight Months After Leading Series A

H1 is a unique healthcare data SaaS company with proprietary data, compelling initial applications, and potential to expand.

December 17, 2020Greg Yap and JP Sanday
loader.svg